Search

Displaying results 2231 - 2240 of 9324 in total
  1. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

  2. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.

    International brands: Ea Ten
  3. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [DB00811] depending on the the presence of resistance associated amino acid substitutions

  4. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    [A215597] It is structurally related to [clobetasol].[A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.

  5. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [L52270] Revakinagene taroretcel delivers CNTF to the retina to lower the extent of neuroregeneration. … [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.

  6. Drug

    Almitrine

    go.drugbank.com/drugs/DB01430
    Approved

    It is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep. … It is used in the treatment of chronic obstructive pulmonary disease.

  7. Drug

    Perflutren

    go.drugbank.com/drugs/DB00556
    ApprovedInvestigational

    When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. … The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image.

  8. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. … [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]

  9. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    296-299 in the protease domain. … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids

  10. Drug

    Aminobenzoic acid

    go.drugbank.com/drugs/DB02362
    ApprovedWithdrawn

    A member of the vitamin B complex. It used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.